EarningsQ2 2026 Earnings Report
IL:EVGN Q2 2026 EPS Results
Actual EPS-42.89
Consensus EPS-82.71
Beat/MissBeat by +39.83
One Year Ago EPS-153.17
IL:EVGN Q2 2026 Revenue Results
Actual Revenue106.30M
Expected Revenue99.56M
Beat/MissBeat by +6.74M
YoY Revenue Growth-60.75%
Earnings Announcement Details
QuarterQ2 2026
Date03/05/2026
TimeBefore Open
Conference CallThursday, March 5, 2026
IL:EVGN Upcoming Earnings
Evogene's next earnings date is estimated for November 18, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
IL:EVGN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Neutral
The call communicated substantial operational and technological progress: a focused shift to ChemPass, meaningful cost and headcount reductions, important platform upgrades (AI agents, predictive models), expanded virtual chemical space, and multiple collaboration agreements validating the platform. These positives are tempered by significant near-term financial and commercialization challenges — materially lower revenue versus prior year, a limited cash balance relative to expected burn, noncash warrant-related accounting volatility, program discontinuation (APTH1), and shareholder governance pressure. Management highlighted actions to raise capital, monetize noncore assets, expand investor outreach, and pursue partnerships, but timelines to convert technological progress into material revenue remain uncertain.Company Guidance
Strategic Transformation to AI-Driven Organization
Company transformed into a lean, AI-driven leader focused on computational chemistry (ChemPass). Headcount reduced from 117 to 38 (≈67.5% reduction) and cash burn reduced from ~$20.5M in 2024 to an expected $8.5–$9.5M in 2026 (≈53–63% reduction).
ChemPass Platform Milestones and Technology Upgrades
ChemPass advanced into a first-in-class generative small molecule foundation model, integrated autonomous AI agents (in partnership with Google Cloud), added new predictive models (e.g., APP antifungal potency predictor), and expanded virtual chemical space from 36 billion to 110 billion molecules (+~206%).
Commercial Validation: Collaboration Agreements
Secured 6 drug development agreements with leading biotechnology companies and academic institutions since entering the small molecule space; 4 new agreements signed since the start of the year and 2 collaborations progressed from Hit ID to Hit-to-Lead.
Internal Drug Discovery Progress
Internal discovery program advanced through Hit-to-Lead (step 2) into Lead Optimization (step 3) with generation of proprietary molecules destined for preclinical candidate selection; management expects at least one internal program could reach preclinical stage in the latter half of next year.
Agriculture Pipeline Advancement
Crop protection program targeting Septoria nearing completion of step 3 (Lead Optimization); synthesized molecules are being tested in advanced biological assays and preparing for greenhouse and field trials, targeting a high-resistance ag market need.
Monetization of Non-Core Assets and Capital Raises
Sold majority of Lavie Bio assets to ICL for $15.25M, licensed Biomica's BMC128 to Lishan Pharmaceuticals, and raised approximately $11.1M in new capital (including ATM proceeds: ~$0.8M in Q2 and ~$2.4M in Q3). Lavie and Biomica distributed dividends: Lavie $4.25M (Evogene share ≈$2.9M) and Biomica $2.7M (Evogene share ≈$1.35M).
Improved Quarterly Profitability Trend
Second quarter 2026 net loss narrowed to ~$1.8M from ~$4.7M in Q2 2025, an improvement of approx. $2.9M (~62% improvement). Consolidated cash and cash equivalents were ~$9.3M as of June 30, 2026; consolidated cash usage in Q2 was ~$2.1M.
Reduced R&D and G&A Spending
R&D (net of grants) for H1 2026 decreased to ~$2.9M from ~$3.5M in H1 2025 (≈17% decrease). Q2 R&D decreased to ~$1.4M from ~$1.7M (≈18% decrease). General & administrative expenses modestly decreased (H1: ~$2.0M vs ~$2.1M prior).
IL:EVGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed